Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.
Stocktwits
More News
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.read more...
Benzinga
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.
Stocktwits
Notable Wednesday Option Activity: OCUL, LLY, WEN
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ocular Therapeutix Inc (Symbol: OCUL), where a total of 25,374 contracts have traded so far, representing approximately 2.5 million underlying shares. That amounts to ab...
Nasdaq News: Markets
OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights
Ocular’s total cash and cash equivalents stood at $598.6 million at the end of the second quarter, which it expects will provide sufficient cash runway until 2028.
Stocktwits
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
Ocular said its U.S. Food and Drug Administration-aligned New Drug Application for wet age-related macular degeneration therapy is expected to be submitted in the fourth quarter of 2026.
Stocktwits
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsOcular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli...
Nasdaq News: Markets
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
Key PointsAcuta Capital Partners reduced its Ocular Therapeutix holding by 460,887 shares...
Nasdaq News: Markets
What This Fund's $14 Million Ocular Therapeutix Exit Could Signal for Investors
Key PointsSaturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million...
Nasdaq News: Markets

Advertisement|Remove ads.